ScoreComparison
Why is Ligand Pharmaceuticals, Inc. ?
1
Company has a low Debt to Equity ratio (avg) at times
2
With a growth in Operating Profit of 73.17%, the company declared Outstanding results in Sep 25
- The company has declared positive results in Jan 70 after 4 consecutive negative quarters
- RAW MATERIAL COST(Y) Fallen by -13.24% (YoY)
- INVENTORY TURNOVER RATIO(HY) Highest at 3.01 times
- NET SALES(Q) Highest at USD 115.46 MM
3
With ROE of 0.48%, it has a attractive valuation with a 4.36 Price to Book Value
- Over the past year, while the stock has generated a return of 92.82%, its profits have fallen by -94.2%
4
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Market Beating performance in long term as well as near term
- Along with generating 92.82% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Ligand Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Ligand Pharmaceuticals, Inc. for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Ligand Pharmaceuticals, Inc.
92.82%
4.50
35.01%
S&P 500
14.9%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
11.86%
EBIT Growth (5y)
43.87%
EBIT to Interest (avg)
-2.40
Debt to EBITDA (avg)
0.21
Net Debt to Equity (avg)
-0.26
Sales to Capital Employed (avg)
0.20
Tax Ratio
69.38%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
1.63%
ROE (avg)
3.89%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
908
Industry P/E
Price to Book Value
4.36
EV to EBIT
136.10
EV to EBITDA
60.32
EV to Capital Employed
5.36
EV to Sales
15.63
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
3.94%
ROE (Latest)
0.48%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Bullish
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend31What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -13.24% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 3.01 times
NET SALES(Q)
Highest at USD 115.46 MM
OPERATING PROFIT(Q)
Highest at USD 62.85 MM
OPERATING PROFIT MARGIN(Q)
Highest at 54.43 %
PRE-TAX PROFIT(Q)
Highest at USD 64.42 MM
NET PROFIT(Q)
Highest at USD 53.53 MM
EPS(Q)
Highest at USD 5.68
-10What is not working for the Company
NET PROFIT(9M)
At USD 19.03 MM has Grown at -68.89%
OPERATING CASH FLOW(Y)
Lowest at USD 31.79 MM
INTEREST(9M)
At USD 2.93 MM has Grown at 36.28%
DEBT-EQUITY RATIO
(HY)
Highest at -22.47 %
Here's what is working for Ligand Pharmaceuticals, Inc.
Net Sales
At USD 115.46 MM has Grown at 146.21%
over average net sales of the previous four periods of USD 46.9 MMMOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Pre-Tax Profit
At USD 64.42 MM has Grown at 558.26%
over average net sales of the previous four periods of USD -14.06 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 53.53 MM has Grown at 543.09%
over average net sales of the previous four periods of USD -12.08 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
Highest at USD 115.46 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 62.85 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at 54.43 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD 64.42 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 53.53 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 5.68
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Inventory Turnover Ratio
Highest at 3.01 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by -13.24% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Ligand Pharmaceuticals, Inc.
Operating Cash Flow
Lowest at USD 31.79 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Interest
At USD 2.93 MM has Grown at 36.28%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Debt-Equity Ratio
Highest at -22.47 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
